Hedge Funds Are Buying Bristol Myers Squibb Co. (BMY)
In the eyes of many of your peers, hedge funds are perceived as useless, outdated financial tools of a forgotten age.
Posts Tagged ‘NYSE:AZN’
AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY), MannKind Corporation (MNKD): Three New Diabetes Drugs Possibly on the Way Soon
It's no wonder that plenty of companies are developing diabetes drugs. There are more than 370 million people with diabetes worldwide.
Osiris Therapeutics, Inc. (OSIR), Anacor Pharmaceuticals Inc (ANAC), Novavax, Inc. (NVAX): Three Humongous Health-Care Stocks This Week
A rising tide lifts all boats, but the opposite isn't true in the stock market. The major indexes slipped this week, while a handful of health-care stocks soared.
Arrowstreet Capital’s Top Picks Include Philip Morris International Inc. (PM), AstraZeneca plc (ADR) (AZN) & More
Arrowstreet Capital was founded by Peter Rathjens, Bruce Clarke, and John Campbell in 1999.
A Smart Eli Lilly & Co. (LLY) Investor Does What Now?
Eli Lilly & Co. (NYSE:LLY) was in 35 hedge funds' portfolio at the end of March. LLY investors should be aware of a decrease in hedge fund interest recently.
GlaxoSmithKline plc (ADR) (GSK), Novartis AG (ADR) (NVS): This Company’s Debt Might Be a Concern
GlaxoSmithKline plc (ADR) (NYSE:GSK) has been accused of making illegal payments to Chinese doctors and government officials by siphoning them through travel agencies.
MannKind Corporation (MNKD), Novo Nordisk A/S (ADR) (NVO), Eli Lilly & Co. (LLY): A Good Drug That’s Too Risky to Buy
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
Medidata Solutions Inc (MDSO), salesforce.com, inc. (CRM): I’m Buying This High-Flying Stock Now
Every month, I select one or more stocks that I'll be buying in real life for my Roth IRA.
Questcor Pharmaceuticals Inc (QCOR), ISIS Pharmaceuticals, Inc. (ISIS): Despite a Mid-Stage Disappointment, This Biotech Stock Is Still in Great Shape
As human beings it can sometimes be difficult for us to see the good in a bad situation.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA), AstraZeneca plc (ADR) (AZN): A Safe Investment With Growth Promise
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been stuck is share purgatory for a number of years.
3 Things You Need to Know From Astex Pharmaceuticals, Inc. (ASTX)’s Q2 Earnings
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) announced its second-quarter financial results on Thursday prior to the market open.
Three Things You Need to Know From Keryx Biopharmaceuticals (KERX)’s Q2 Earnings
Keryx Biopharmaceuticals (NASDAQ:KERX) announced its second-quarter results before the market opened on Thursday.
Array Biopharma Inc (ARRY), AstraZeneca plc (ADR) (AZN), GlaxoSmithKline plc (ADR) (GSK): This Cancer Biotech Is Looking for Other Green Pastures
Array Biopharma Inc (NASDAQ:ARRY), a biotech company primarily focused on discovery of drugs for cancer treatment, is making forays into the asthma market.
China Petroleum & Chemical Corp (ADR) (SNP), AstraZeneca plc (ADR) (AZN): Three Companies With Dividend Yields You Don’t Want to Miss
Several companies are striving hard to manage their business and retain investors by providing an attractive dividend.
Three Things You Need to Know From Merck & Co., Inc. (MRK)’s Q2 Earnings
The good news was that the big pharmaceutical company beat earnings estimates. Merck & Co., Inc.
Pharma News: Vivus, Inc. (VVUS)’s New CEO, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Positive Earnings
VIVUS, Inc. (NASDAQ:VVUS), which sells the obesity drug Qsymia, has appointed Anthony Zook to serve as its CEO.
AstraZeneca plc (ADR) (AZN) and Bristol Myers Squibb Co. (BMY): 2 Keys to Success for This Diabetes Drug’s Second Chance
AstraZeneca plc (ADR) (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) announced last week that they are making another attempt at U.S.
Bristol Myers Squibb Co. (BMY), AstraZeneca plc (ADR) (AZN): Expanding P/E Saved This Pharma Investment
Three years ago, the company told investors not to worry. It had a plan to replace the $6 billion drug that lost patent protection last year.
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN): Will This Biotech Bidding War Lead You to Larger Gains?
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout.
Pfizer Inc. (PFE), GlaxoSmithKline plc (ADR) (GSK): Three Healthcare Stocks for Growth and Dividends
The healthcare sector has been one of the best sectors for dividend hunters -- most of the companies operating in the sector generate massive cash flow and payout a large chunk...
AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY): The Diabetes Pipeline With a Clog
Big pharma placed its bets on a new class of diabetes drugs called SGLT2. Last year, buzz surrounded late-stage projects from Johnson and Johnson (NYSE:JNJ), Eli Lilly & Co.
Four Potential Suitors for Onyx Pharmaceuticals, Inc. (ONXX)
The "people familiar with the matter" are out in full force spouting off about who's bidding for Onyx Pharmaceuticals, Inc.
AstraZeneca plc (ADR) (AZN), Actavis Inc (ACT): Can Fish Oil Help This Drug Giant Regain its Mojo?
AstraZeneca plc (ADR) (NYSE:AZN)’s financial results have been on a downward spiral lately, as patent expirations have led to sharp declines in sales of its leading drugs.
Amarin Corporation plc (ADR) (AMRN) Shares Sink on Secondary Offering
"More means less." Amarin Corporation plc (ADR) (NASDAQ:AMRN) demonstrated this seemingly contradictory maxim today following its announcement of a new public offering.
The Medicines Company (MDCO), AstraZeneca plc (ADR) (AZN): A Small-Cap Pharmaceutical Company With 2014 in Its Sights
A few months back, Barron's featured an intriguing pharmaceutical company that goes by the name The Medicines Company (NASDAQ:MDCO).
How Much Is Onyx Pharmaceuticals, Inc. (ONXX) Really Worth?
The promising cancer developer confirmed over the weekend that Amgen had made an offer to acquire Onyx for $120 per share, a 38.2% premium above Friday's close.
TAL International Group, Inc. (TAL), Annaly Capital Management, Inc. (NLY) – High Yield: Stocks or Bonds?
A few weeks ago, CAPS player Valyooo started a lively debate with a blog entry asking for opinions on stocks vs. high-yield bonds.
AstraZeneca plc (ADR) (AZN), PDL BioPharma Inc. (PDLI): Tempting Healthcare Dividend Stocks to Avoid
When screening for health-care dividend stocks, it's tempting to look for the ones with the highest yield.
ISIS Pharmaceuticals, Inc. (ISIS): This Anti-Sense Bet Makes Sense
In the last couple of years, the biotechnology industry has been on a roll.
Merck & Co., Inc. (MRK) Stock Depends on Januvia More Than Ever
Merck & Co., Inc. (NYSE:MRK) stock has become dependent on its diabetes drug Januvia over the past couple of years for revenue growth.
AstraZeneca plc (ADR) (AZN), Sanofi SA (ADR) (SNY): Don’t Ignore These European Healthcare Stocks
Healthcare stocks have rallied over the past couple years, and for good reason.
Amarin Corporation plc (ADR) (AMRN), AstraZeneca plc (ADR) (AZN), Omthera Pharmaceuticals Inc (OMTH): Three Stocks Near 52-Week Lows Worth Buying
Just as we examine companies each week that may be rising past their fair value, we can also find companies potentially trading at bargain prices.
What These Ratios Tell Us About GlaxoSmithKline plc (ADR) (GSK)
These two ratios provide an indication of how successful a company is at generating profits using shareholders' funds and debt, and they have a strong influence on dividend payments...
AstraZeneca plc (ADR) (AZN), GlaxoSmithKline plc (ADR) (GSK): Will These Pharma Stocks Maintain Their Yields?
High dividend pharmaceutical stocks have been extremely popular in recent years.
Why I Think GlaxoSmithKline plc (GSK) Is So Much More Than Just an Income Stock
Indeed, the shares currently yield an impressive 4.4% despite rising by more than 30% in the last three years alone.
AstraZeneca plc (ADR) (AZN): Is This Purchase a Game-Changer?
London-based pharmaceutical giant AstraZeneca plc (ADR) (NYSE:AZN) recently announced that it had agreed to purchase U.S.-based lung-drug manufacturer Pearl Therapeutics for at...
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Top Treatments for High Cholesterol
About a third of American adults have high LDL cholesterol -- that's the bad kind -- but less than half of adults with high LDL seek treatment, according to the Centers for Disease...
Eli Lilly & Co. (LLY), Merck & Co., Inc. (MRK): Another Alzheimer’s Disease Failure
The latest drug to bite the dust is LY2886721, a beta secretase, or BACE, inhibitor.
AstraZeneca plc (ADR) (AZN), GlaxoSmithKline plc (ADR) (GSK): A Big Pharma Company With a Juicy Dividend Yield and Low Valuation
Recently, AstraZeneca plc (ADR) (NYSE:AZN) announced that it has agreed to acquire Pearl Therapeutics, the respiratory drug manufacturer, in a transaction worth around $1.15 billion...
Pfizer Inc. (PFE), Puma Biotechnology Inc (PBYI): Strong Product Pipelines Have Pharmaceutical Companies Poised for Growth
With the global economy beginning to stabilize, the stock market is looking more attractive than ever.
The Stock Picker’s Guide to AstraZeneca plc (AZN)
In this series, I'm subjecting companies to scrutiny under five headings: prospects, performance, management, safety, and valuation.
AstraZeneca plc (ADR) (AZN), Novartis AG (ADR) (NVS): 5 Biotech Giants with Lucrative Dividend Yields
Investing in biotech stocks is relatively risky amid the volatility of the market. There are many factors that can greatly affect share trends and price performance.
Pfizer Inc. (PFE), AstraZeneca plc (ADR) (AZN): Is Concentration Better Than Diversification in Pharma?
Pfizer Inc. (NYSE:PFE) recently completed the spin-off of its animal health unit, Zoetis Inc (NYSE:ZTS).
ACADIA Pharmaceuticals Inc. (ACAD): What’s Next For This Biotech?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’ 1,100% gain makes it one of the best performing stocks in the market.
Regeneron Pharmaceuticals Inc. (REGN), GlaxoSmithKline plc (GSK): The First Real Cure in the $25 billion Asthma Market?
Everyone has had a friend at school who was asthmatic. Life is not easy for the chronic asthmatic.
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Looking to Return Capital to Shareholders Via Debt-Fueled Share Buyback
Pharmaceutical giant Merck & Co., Inc.
Amarin Corporation plc (ADR) (AMRN), AstraZeneca plc (ADR) (AZN): A Winning Biotechnology Bet
Amarin Corporation plc (ADR) (NASDAQ:AMRN) has recently launched its primary product candidate Vascepa into the market.
AstraZeneca plc (ADR) (AZN)’s Acquisition of Omthera Pharmaceuticals Inc (OMTH) Is a Desperate Act
AstraZeneca plc (ADR) (NYSE:AZN) announced the acquisition of Omthera Pharmaceuticals Inc (NASDAQ:OMTH), a company that went public just last month (April 11).
GlaxoSmithKline plc (ADR) (GSK), Merck & Co., Inc. (MRK): Why You Should Care About This Diabetes Drug Saga
GlaxoSmithKline plc (ADR) (NYSE:GSK)'s diabetes drug Avandia causes heart issues. Or maybe it doesn't.
Rigel Pharmaceuticals, Inc. (RIGL), Synta Pharmaceuticals Corp. (SNTA): Three Horrendous Health-Care Stocks This Week
Many stocks encountered turbulence this week, but few were blown about like several biotech stocks.
